FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Anxiety patents



      
           
This page is updated frequently with new Anxiety-related patents. Subscribe to the Anxiety RSS feed to automatically get the update: related Anxiety RSS feeds.

Subscribe to updates on this page: Anxiety RSS RSS

Date/App# patent app List of recent Anxiety-related patents
04/17/14
20140107398
 Methods and devices for treating primary headache patent thumbnailnew patent Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
04/17/14
20140107397
 Methods and devices for treating primary headache patent thumbnailnew patent Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
04/17/14
20140107108
 Compositions comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and process for preparing them patent thumbnailnew patent Compositions comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and process for preparing them
Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the x-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution.
04/10/14
20140096767
 Nasal aroma breathing pipe patent thumbnailNasal aroma breathing pipe
The claimed invention is an apparatus to assist and encourage a person to take long, deep and steady breaths. The invention is designed to provide improved health for the user by fostering; improved breathing and relaxation, positive smell association, calmer clearer thinking, reduced stress and anxiety, as well as providing a substitute for potentially harmful habits such as smoking, over-eating, over-drinking and other forms of drug abuse.
03/27/14
20140088104
 Novel small-molecules as therapeutics patent thumbnailNovel small-molecules as therapeutics
The present invention provides compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression..
03/20/14
20140081071
 Methods and devices for treating primary headache patent thumbnailMethods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
03/20/14
20140081025
 Heteroaromatic ring derivative patent thumbnailHeteroaromatic ring derivative
Or a pharmaceutically acceptable salt thereof is based on orexin (ox) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.. .
03/06/14
20140066504
 Analogs and prodrugs of bumetanide; compositions and methods of use patent thumbnailAnalogs and prodrugs of bumetanide; compositions and methods of use
Novel analogs and prodrugs of the loop diuretic bumetanide are described. Pharmaceutical compositions containing bumetanide analogs and prodrugs are also described.
02/13/14
20140045839
 Novel anxiolytic compounds patent thumbnailNovel anxiolytic compounds
Which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.. .
01/23/14
20140024658
 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride patent thumbnailPolymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
01/16/14
20140018549
Use of d-serine derivatives for the treatment of anxiety disorders
Compounds of formula i are useful for the treatment of anxiety disorders such as generalized anxiety disorder (gad), panic attack, post traumatic stress disorder (ptsd), obsessive compulsive disorder (ocd) and social phobias, wherein: a is chosen from: aryl or heteroaryl, a being optionally substituted with up to 5 independently-selected groups r8; r1 is chosen from: alkyl or haloalkyl; r2 is chosen from: h, c(o)r6, c(o)or6, so2r6 or c(o)nr6r7; r3, r4 and r5 are independently chosen from: h or alkyl; r6 and r7 are independently chosen from: h or alkyl; and r8 is chosen from: oh, cn, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, c(o)r6, c(o)or6, so2r6 or c(o)nr6r7.. .
12/26/13
20130345241
Dihydrooxazol-2-amine derivatives
Or to a pharmaceutically acceptable acid addition salt thereof. Compounds of formula i have a good affinity to the trace amine associated receptors (taars), especially for taar1.
12/12/13
20130331571
Glycine transporter-inhibiting substances
The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .
10/24/13
20130281465
Pyrazole derivative
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which is useful for the treatment or prevention of diseases such sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, pain, gastrointestinal diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases, and hypertension, and of which the action relies on an orexin (ox) receptor antagonistic activity.. .
08/15/13
20130210783
Neuroactive steroid compositions and methods of use therefor
Provided are methods for ameliorating a symptom of a neuropsychiatric disorder. Also provided are methods for ameliorating at least one symptom resulting from tobacco cessation; and for ameliorating a symptom of alzheimer's disease or other cognitive disorder; of schizophrenia, schizoaffective disorder, or other psychotic disorder; of a depressive disorder; of bipolar disorder; of post-traumatic stress disorder or other anxiety disorder; of a pain disorder; or of traumatic brain injury.
08/15/13
20130210714
Protein-bound tryptophan food composition
A composition comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, which plant source has been processed to at least partially remove oil contained therein to yield said meal having a natural source of tryptophan greater than its plant source, a carbohydrate source having a high glycemic index and a physiologically-acceptable diluent or carrier therefor for inducing sleep, alleviating an anxiety disorder, depression, obsessive compulsive aggression, chronic pain or eating disorder, in a human in need thereof, wherein said composition is in the form of a food bar further comprising a puffed cereal. The composition provides improved sleep characteristics..
08/01/13
20130197217
1, 2, 4-triazolone derivative
The present invention provides a 1,2,4-triazolone derivative represented by formula (1a) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.. .
07/18/13
20130184639
Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
A system and method for introducing one or more stimulating drugs and/or applying electrical stimulation to the brain to treat mood and/or anxiety disorders uses an implantable system control unit (scu), specifically an implantable signal/pulse generator (ipg) or microstimulator with one or more electrodes in the case of electrical stimulation, and an implantable pump with one or more catheters in the case of drug infusion. In cases requiring both electrical and drug stimulation, one or more scus are used.
07/18/13
20130184460
Glycine transporter inhibiting substances
The present invention aims to provide novel compounds of formula [i] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, pain, and sleep disorder:. .
07/18/13
20130184294
Pyrimidones for treatment of potassium channel related diseases
The present invention relates to compounds of formula i as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of formula i or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.. .
07/11/13
20130178913
Methods for targeting deep brain sites to treat mood and/or anxiety disorders
The present invention relates to a method of identifying a target such as within the subgenual area by measuring neuronal activity in response to a stimulus. Once the target is identified, it can be stimulated to treat a neurological disorder, such as a mood disorder or an anxiety disorder..
07/04/13
20130172418
Pharmaceutical composition comprising n-acetyl-l-cysteine or its derivatives for treating anxiety disorder
The present disclosure relates to a composition for treating anxiety disorder, particularly to a pharmaceutical composition comprising n-acetyl-l-cysteine or its derivatives for treating anxiety disorder such as post traumatic stress disorder or phobia. In accordance with the present disclosure, n-acetyl-l-cysteine can block the renewal of fear memories for a sustained period of time when it was administered during or after an exposure therapy to treat post traumatic stress disorder or phobia..
06/13/13
20130150391
Piperidinyl pyrimidine amides as kv7 potassium channel openers
The present invention relates to compounds of formula (i) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of formula (i) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.. .
06/13/13
20130149370
Herbal composition for preventing and/or treating anxiety related conditions
The present invention relates to herbal compositions for the treatment and/or prevention of anxiety disorders or stress. These compositions comprise hawthorn fruit (shan zha), light wheat grain (fu xiao mai) and lilly bulb (bai hi) in amounts which are effective to treat anxiety conditions.
06/06/13
20130142847
S-adenosylmethionine formulations with enhanced bioavailability
Provided herein are compositions and methods to enhance the absorption of s-adenosylmethionine (same) and methods of treating various disorders or diseases using non-parenteral same formulations with enhanced-absorption and improved bioavailability. In certain embodiments, the enhanced bioavailability formulations provided herein may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g.
05/30/13
20130137865
Heteroaryl-pyrazole derivative
A compound represented by formula [i] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group ii metabotropic glutamate (mglu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.. .
05/16/13
20130123500
Ethinyl-pyrazole derivative
Provided is a novel compound represented by formula [i] or a pharmaceutically acceptable salt thereof having antagonistic activity against group ii metabolism-type glutamic acid (m-glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like..
04/25/13
20130102616
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
04/18/13
20130096089
Heterocyclic compounds for the treatment of neurological and psychological disorders
Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
03/21/13
20130068172
Kennel with automatically opening door
The present invention seeks to prevent damage to property resulting from an animal's separation anxiety which occurs when a pet owner departs, while minimizing the period of time the dog is confined. The device incorporates an automatically releasing door of a kennel or leash.
03/14/13
20130065904
Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone.
01/31/13
20130028994
Pomegranate extract having a high ellagic acid content, and use of the pomegranate extract
A pomegranate pulp extract is disclosed. The pomegranate pulp extract is effective in relieving women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders due to the presence of a large amount of ellagic acid.
01/31/13
20130028842
Method of treating binge eating disorder
The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in adhd and add patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in adhd and add patients.
01/10/13
20130012509
Novel anxiolytic compounds
Which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.. .
01/10/13
20130012508
Novel anxiolytic compounds
Which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.. .


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Anxiety for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anxiety with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.285

3922

1 - 1 - 73